Forster M., Brealey S., Chick S., Keding A., Corbacho B., Alban A., Pertile P., Rangan A. (2021). Cost-effective clinical trial design: Application of a Bayesian…
Levaggi R., Pertile P. (2021). A reply to “Who would benefit from average value-based pricing?”. Health Economics, Volume 30(9), pp. 2284-2286. Abstract: This is…
Gamba S., Magazzini L., Pertile P. (2021). R&D and market size: Who benefits from orphan drug legislation?. Journal of Health Economics, 80, 102522. Abstract: Since the…
Levati R., Pertile P. (2020). Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition. Applied Health Economics and Health Policy, Volume 18,…
Levaggi R., Pertile P. (2020) Which valued-based price when patients are heterogeneous? Health economics, Volume 29, Issue 8, pp. 923-935. Abstract: We use a…
Levaggi R., Pertile P. (2020). Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition”. Applied health…
Gamba S., Pertile P., Vogler S. (2020) The impact of managed entry agreements on pharmaceutical prices. Health Economics, Volume 29, Issue 51, pp. 47-62. …
Gamba S., Magazzini L., Pertile P. (2019). R&D and market size: who benefits from orphan drug regulation?. Working Paper Series, Department of Economics, University of…
Vogler S., Pertile P., Gamba S. (2019) Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies. Journal of Pharmaceutical Policy and…
Biscardo C. A., Bucciol A., Pertile P. (2019) Job Sick Leave: Detecting Opportunistic Behavior. Health Economics, vol. 28, n.3, 2019, pp. 373-386. Abstract: We utilize…
